@article{10902/23650,
year = {2021},
month = {12},
url = {http://hdl.handle.net/10902/23650},
abstract = {Nursing home residents (NHR) have been targeted as a vaccination priority due to their higher risk of worse outcome after COVID-19 infection. The mRNA-based vaccine BTN2b2 was first approved in Europe for NHRs. The assessment of the specific vaccine immune response (both humoral and cellular) at long term in NHRs has not been addressed yet. A representative sample of 624 NHR subjects in Northern region of Spain was studied to assess immune response against full vaccination with BTN2b2. The anti-S1 antibody levels and specific T cells were measured at two and six months after vaccination. 24.4% of NHR had a previous infection prior to vaccination. The remaining NHR were included in the full vaccination assessment group (FVA). After two months, a 94.9% of the FVA presented anti-S1 antibodies, whereas those seronegative without specific cellular response were 2.54%. At long-term, the frequency of NHR within the FVA group with anti-S1 antibodies at six months were 88.12% and the seronegative subjects without specific cellular response was 8.07%. The cellular immune assays complement the humoral test in the immune vaccine response assessment. Therefore, the cellular immune assessment in NHRs allows for the fine tuning of those seronegative subjects with potential competent immune responses against the vaccine.},
publisher = {MDPI},
publisher = {Vaccines 2021, 9(12), 1429},
title = {COVID-19 mRNA Based Vaccine Immune-Response Assessment in Nursing Home Residents for Public Health Decision},
author = {San Segundo, David and Comins-Boo, Alejandra and Lamadrid-Perojo, Patricia and Irure Ventura, Juan and Castillo Oti, José María and Wallman, Reinhard and Calvo-Montes, Jorge and Méndez-Legaza, José Manuel and Baamonde-Calzada, Carmela and Sánchez-Molina, Isabel and Lecue-Martínez, Marina and Ventisca-Pérez, Silvia and Batllé López, Ana and López Hoyos, Marcos},
}